Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Recombinant virus encoding one or more heterologous proteins...
Reexamination Certificate
2011-05-17
2011-05-17
Mosher, Mary E (Department: 1648)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Recombinant virus encoding one or more heterologous proteins...
C435S235100, C435S320100, C424S231100, C424S093200
Reexamination Certificate
active
07943144
ABSTRACT:
There is provided an HSV Complex which comprises an avirulent HSV and a targeting agent which allows the HSV particle to infect and lyse a specific targeted cell. The inventors have found a way in which avirulent HSV can be targeted to disease cells, e.g. cancer cells, by incorporating an antibody binding domain into one or more viral glycoproteins.
REFERENCES:
patent: 6139834 (2000-10-01), Martuza et al.
patent: 6235467 (2001-05-01), Brown et al.
patent: 6673602 (2004-01-01), Spear et al.
patent: 2 374 873 (2002-10-01), None
patent: 6-507066 (1994-08-01), None
patent: WO 92/13943 (1992-08-01), None
patent: WO 92/13943 (1992-08-01), None
patent: WO 96/03997 (1996-02-01), None
patent: WO 98/39467 (1998-09-01), None
patent: WO 98/42195 (1998-10-01), None
patent: WO 99/06583 (1999-02-01), None
patent: WO 00/08191 (2000-02-01), None
patent: WO 01/16331 (2001-03-01), None
patent: 2004/033639 (2004-04-01), None
patent: WO 2009/013448 (2009-01-01), None
Chung et al. M-myb Promoter Retargeting of Herpes Simplex Virus y34.5 Gene-Mediated Virulence toward Tumor and Cycling Cells. Journal of Virology, Sep. 1999, vol. 73, No. 9, pp. 7556-7564.
Weng et al. Expression of complement inhibitors CD46, CD55 and CD59 on tumor cells does not predict clinical outcome after rituximab treatment in follicular non-Hodgkin lymphoma. Blood, Sep. 2001, vol. 98, No. 5, pp. 1352-1357.
MacKie et al. Intralesional injection of herpes simplex virus 1716 in metastatic melanoma. The Lancet, Feb. 2001, vol. 357, pp. 525-526.
Somia et al. Proc. Natl.l Acad. Sci. USA, 1995, vol. 92, pp. 7570-7574.
Hammond et al. Journal of Virology, Mar. 2000, vol. 75, No. 5, pp. 2087-2096.
Laquerre et al (Journal of Virology 72:9683-9697, 1998).
Zhou et al (PNAS 99:15124-15129, Nov. 2002).
Menotti et al (Journal of Virology 80:5531-5539, 2006).
Connor et al (Gene Therapy 15:1579-1592, 2008).
Ager, et al., “Retroviral Display of Antibody Fragments; Interdomain Spacing Strongly Influences Vector Infectivity,”Human Gene Therapy, 7:2157-2164 (Nov. 10, 1996).
Arakawa, et al., “Targeting of T Cells to CEA-expressing Tumor Cells by Chimeric Immune Receptors with a Highly Specific Single-chain Anti-CEA Activity,”Anticancer Research, 22:4285-4290 (2002).
Benedict, et al., “Targeting Retroviral Vectors to CD34-Expressing Cells: Binding to CD 34 Does Not Catalyze Virus-Cell Fusion,”Human Gene Therapy, 10:545-557 (Mar. 1, 1999).
Bucheit, et al., “An Oncolytic Measles Virus Engineered to Enter Cells Through the CD20 Antigen,”Molecular Therapy, 7(1):62-72 (Jan. 2003).
Engelstädter, et al., “Targeting Human T Cells by Retroviral Vectors Displaying Antibody Domains Selected from a Phage Display Library,”Human Gene Therapy, 11:293-303 (Jan. 20, 2000).
Galmiche, et al., “Expression of a functional single chain antibody on the surface of extracellular enveloped vaccinia virus as a step towards selective tumour cell targeting,”J. of General Virology, 78:3019-3027 (1997).
Khare, et al.. “Specifically Targeted Killing of Carcinoembryonic Antigen (CEA)-expressing Cells by a Retroviral Vector Displaying Single-Chain Variable Fragmented Antibody to CEA and Carrying the Gene for Inducible Nitric Oxide Synthase,”Cancer Research, 61:370-375 (Jan. 1, 2001).
Konishi, et al., “Targeting Strategy for Gene Delivery to Carcinoembryonic Antigen-Producing Cancer Cells by Retrovirus Displaying a Single-Chain Variable Fragment Antibody,”Human Gene Therapy, 9:235-248 (Jan. 20, 1998).
Kuroki, et al., “Specific Targeting Strategies of Cancer Gene Therapy Using a Single-chain Variable Fragment (scFv) with a High Affinity for CEA,”Anticancer Research, 20:4067-4072 (2000).
Laquerre, et al., “Recombinant Herpes Simplex Virus Type 1 Engineered for Targeted Binding to Erythropoietin Receptor-Bearing Cells,”J. of Virology, 72(12):9683-9697 (Dec. 1998).
Lilley, et al., “Multiple Immediate-Early Gene-Deficient Herpes Simplex Virus Vectors Allowing Efficient Gene Delivery to Neurons in Culture and Widespread Gene Delivery to the Central Nervous System in Vivo,”J. of Virology, 75(9):4343-4356 (May 2001).
Marin, et al., “Targeted Infection of Human Cells via Major Histocompatibility Complex Class I Molecules by Moloney Murine Leukemia Virus-Derived Viruses Displaying Single-Chain Antibody Fragment-Envelope Fusion Proteins,”J. of Virology, 70(5):2957-2962 (May 1996).
Martin, et al., “Retrovirus Targeting by Tropism Restriction to Melanoma Cells,”J. of Virology, 73(8):6923-6929 (Aug. 1999).
Martin, et al., “Retroviral Vector Targeting to Melanoma Cells by Single-Chain Antibody Incorporation in Envelope,”Human Gene Therapy, 9:737-746 (Mar. 20, 1998).
McKie, et al., “Histopathological responses in the CNS following inoculation with a non-neurovirulent mutant (1716) of herpes simplex virus type 1 (HSV 1): relevance for gene and cancer therapy,”Neuropathology and Applied Neurobiology, 24:367-372 (1998).
McKie, et al., “Selective astrocytic transgene expression in vitro and in vivo from the GFAP promoter in a HSV RL1 null mutant vector—potential glioblastoma targeting,”Gene Therapy, 5:440-450 (1998).
McKie, et al., “Selective in vitro replication of herpes simplex virus type 1 (HSV-1) ICP34.5 null mutants in primary human CNS tumours-evaluation of a potentially effective clinical therapy,”British J. of Cancer, 74:745-752 (1996).
Peng, et al., “Oncolytic measles viruses displaying a single-chain antibody against CD38, a mycloma cell marker,”Blood, 101(7):2557-2562 (Apr. 1, 2003).
Schnierle, et al., “Expression of chimeric envelope proteins in helper cell lines and integration into Moloney murine leukemia virus particles,”Gene Therapy, 3:334-342 (1996).
Spear, et al., “HSV-1 amplicon peptide display vector,”J. Virological Methods, 107:71-79 (2002).
Taha, et al., “A Variant of Herpes Simplex Virus Type 2 Strain HG52 with a 1.5 kb Deletion in RLbetween 0 and 0.02 and 0.81 to 0.83 Map Units Is Non-neurovirulent for Mice,”J. General Virology, 70:705-716 (1989).
Tanaka, et al, “Targeted killing of carcinoembryonic antigen (CEA)-producing cholangiocarcinoma cells by polyamidoamine dendrimer-mediated transfer of an Epstein-Barr virus (EBV)-based plasmid vector carrying the CEA promoter,”Cancer Gene Therapy, 7(9):1241-1249 (2000).
Tang and Qian, “Tumor cell-specific gene transfer with retroviral vectors displaying single-chain antibody,”Chinese Medical Journal, 115(7):1064-1069 (2002).
Toda, et al., “Herpes Simplex Virus as an in Situ Cancer Vaccine for the Induction of Specific Anti-Tumor Immunity,”Human Gene Therapy, 10:385-393 (Feb. 10, 1999).
Watkins, et al., “The ‘adenobody’ approach to viral targeting: specific and enhanced adenoviral gene delivery,”Gene Therapy4:1004-1012 (1997).
Wickham, “Ligand-directed targeting of genes to the site of disease,”Nature Medicine, 9(1):135-139 (Jan. 2003).
Kirn et al. “Replication-selective virotherapy for cancer: Biological principles, risk management and future directions,”Nature Medicine7(7): 781-787 (2001).
Post et al. “Replicative Oncolytic Herpes Simplex Viruses in Combination Cancer Therapies,”Current Gene Therapy4: 41-51 (2004).
Tolba et al. “Development of herpes simplex firus-1 amplicon-based immunotherapy for chronic lymphocytic leukemia,”Gene Therapy. Blood.98(2): 287-295 (2001).
Laquerre, Sylvie et al., “Recombinant Herpes Simplex Virus Type 1 Engineered for Targeted Binding to Erythropoietin Receptor-Bearing Cells,” Journal of Virology, Dec. 1998, pp. 9683-9697, vol. 72, No. 12, Copyright 1998, American Society for Microbiology.
Menotti, Laura, et al., “A Herpes Simplex Virus Recombinant That Exhibits a Single-Chain Antibody to HER2
eu Enters Cells through the Mammary Tumor Receptor, Independently
Brown Susanne Moira
Conner Joe
Crusade Laboratories Limited
Mosher Mary E
Swanson & Bratschun L.L.C.
LandOfFree
Herpes simplex virus complex does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Herpes simplex virus complex, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Herpes simplex virus complex will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2660822